176 related articles for article (PubMed ID: 33328591)
1. Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Morschhauser F; Dyer MJS; Walter HS; Danilov AV; Ysebaert L; Hodson DJ; Fegan C; Rule SA; Radford J; Cartron G; Bouabdallah K; Davies AJ; Spurgeon S; Rajakumaraswamy N; Li B; Humeniuk R; Huang X; Bhargava P; Jürgensmeier JM; Salles G
Leukemia; 2021 Jul; 35(7):2108-2113. PubMed ID: 33328591
[No Abstract] [Full Text] [Related]
2. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
[TBL] [Abstract][Full Text] [Related]
3. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
7. Idelalisib, ibrutinib show benefits in CLL.
Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
[No Abstract] [Full Text] [Related]
8. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
[TBL] [Abstract][Full Text] [Related]
9. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
12. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
Lamanna N
Oncology (Williston Park); 2015 Jun; 29(6):443, 445. PubMed ID: 26091680
[No Abstract] [Full Text] [Related]
13. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Flinn IW
Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
[No Abstract] [Full Text] [Related]
14. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
[TBL] [Abstract][Full Text] [Related]
15. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
17. In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
Tarantelli C; Gaudio E; Cascione L; Stathis A; Zucca E; Bertoni F
Br J Haematol; 2019 Jul; 186(1):149-152. PubMed ID: 30569468
[No Abstract] [Full Text] [Related]
18. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
Fruman DA; Cantley LC
N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
[No Abstract] [Full Text] [Related]
19. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Godet S; Protin C; Dupuis J; Dartigeas C; Bastie JN; Herbaux C; Leblond V; de Guibert S; Ghez D; Brion A; Ysebaert L; Delmer A; Quinquenel A
Am J Hematol; 2018 Feb; 93(2):E52-E54. PubMed ID: 29164674
[No Abstract] [Full Text] [Related]
20. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
